Merck's Financial Performance in Q1 2025

In the first quarter of fiscal 2025, Merck & Co., Inc. experienced a 2% year-on-year decline in sales, totaling $15.5 billion. Despite this, the company showcased a robust increase in net income and earnings per share, signaling a strong start to the year.

Earnings and Strategic Progress

Net income for the quarter rose by 7% to $5.1 billion, with diluted earnings per share (EPS) also increasing by 7% to $2.01. Robert M. Davis, Chairman and CEO, highlighted the company's progress, emphasizing the growing contributions from newer medicines and vaccines, as well as advancements in the pipeline.

Market Response

Following the announcement, Merck's stock saw a premarket increase of 0.98%, trading at $79.51 per share at 6:38 am ET.